Skip to main content
. 2021 Feb 15;13(2):149. doi: 10.3390/toxins13020149

Figure 2.

Figure 2

An overview of the mPFS and mOS in the context of hepatocellular carcinoma [37,38,39], urothelial [87,89,90] and non-small cells lung cancer [49,50]. mPFS, median progression-free survival, mOS, median overall survival.